ClinicalTrials.gg
RecruitingNCT04441203SELFIe-HFUpdated Nov 22, 2024

Patient SELF-management With HemodynamIc Monitoring: Virtual Heart Failure Clinic and Outcomes

An interventional study of CardioMems in Chronic Heart Failure, sponsored by Montreal Heart Institute. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by Montreal Heart Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started May 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Heart Failure by Montreal Heart Institute — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · Montreal Heart Institute.

Planned enrollment
5th of 15
150 · median 120
Started
2020
the only one that year
No phase
8 of 22
2 open now
Registered
15th of 22
by date

Among the 22 studies in Heart Failure by Montreal Heart Institute, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2020, is one of 8 with no phase, and was the 15th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 22 studies in Heart Failure by Montreal Heart Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Heart Failure by Montreal Heart Institute, or all of them as a file.
02

Study summary

To demonstrate that a virtual Heart Failure Clinic (HFC) based on patient self-management using Pulmonary Artery Pressure (PAP) monitoring is superior to usual care of HFC, leads to decreased: hospital admissions for heart failure (HF), emergency department consultation and/or unplanned intravenous heart failure therapy and cardiovascular death, compared to a regular HFC, has low device-related complications and is cost-effective, in New York Heart Association (NYHA) class III and II (requiring diuretics) patients.

Read the detailed description

This will be a single center, prospective, randomized, open-label blinded-endpoint (PROBE) trial in which the treatment group will be implanted with a CardioMEMS HF sensor and managed using remote access to hemodynamics compared to a non-implanted control group. Patients with at least one hospitalization for HF (≥1) in the previous year (12 months) will be randomized into two groups, regardless of LVEF:

Usual care with the specialized multidisciplinary HF clinic team (Non-implanted Control) or Hemodynamic monitoring, less intense HF clinic follow-up, and remote follow-up by a nurse clinician and patient empowerment with access to the PAP data (CardioMEMS group).

Primary and secondary endpoints will be compared between groups after 12 months of follow-up and within groups comparing baseline parameters with 12 month follow-up measurements.

03

Conditions studied

  • Chronic Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years old.
  2. Symptomatic HF ( III) with recent heart failure admission in the previous year (12 months). OR
  3. Patient with at least one ER visit or unplanned HF clinic requiring iv diuretics within 12 months will be eligible if they have in addition a N-terminal pro-BNP (NT-proBNP) level > 800pg/ml at screening AND NYHA Class II on diuretics (furosemide ≥ 40mg qd), III or ambulatory IV.
  4. HF with reduced or preserved EF of at least 3 months duration.
  5. Minimum technological knowledge either with a smartphone or iPAD for use of the self-management application, including access to internet.
  6. Anatomical criteria

    1. PA branch diameter between 7 mm - 15 mm
    2. For >35, distance from patient's back to target PA\<10cm

Exclusion criteria

Exclusion Criteria:

  1. Recent cardiovascular event: Acute coronary syndrome (STEMI/NSTEMI; a small rise in the troponin level would be expected in this population and is not a for enrolment); Percutaneous Coronary Intervention (PCI), new cardiac rhythm management (CRM) device (pacemaker, ICD and CRT), CRM system revision, lead extraction or cardiac or other major surgery or or stroke within 2 months (3 months of stabilization after CRT or cardiac surgery);
  2. Scheduled cardiac surgery;
  3. History of pulmonary embolism or recurrent deep vein thrombosis;
  4. Persistent Class IV and ACC/AHA HF Stage D, patients implanted with a ventricular assist device (VAD), or patients listed for cardiac transplantation and likely to be transplanted within 12 months;
  5. Coexisting severe stenotic valve lesions, endocarditis, obstructive hypertrophic cardiomyopathy, acute myocarditis, tamponade, or large pericardial effusion;
  6. Clinically too unstable to be followed remotely; this includes but is not limited to:

    1. Resting systolic blood pressure \< 80 or > 180 mmHg;
    2. Resting heart rate > 100 bpm;
    3. Stage IV or V chronic kidney disease (Estimated (eGFR) that remains \< 30 mL/min/1.73m2 by MDRD) or nonresponsive to diuretic therapy or on chronic renal dialysis;
  7. Severe pulmonary hypertension with systolic pulmonary artery pressure ≥80 mmHg;
  8. Pulmonary hypertension other than group II PH;
  9. Anemia requiring transfusions, iron infusions, or below 100;
  10. Coagulopathy or uninterruptible anticoagulation therapy or contraindication to antiplatelet/anticoagulant treatments anticipated in the protocol;
  11. Intolerance to aspirin or clopidogrel;
  12. Active infection requiring systemic antibiotics;
  13. Unwillingness to sign or to attend the outpatient clinic;
  14. Participation in another research trial with intervention;
  15. Discharge to a chronic care facility or residence in an outlying area;
  16. Pregnant or lactating women or women of who are not protected from pregnancy by an accepted method of , such as the oral contraceptive pill, an intrauterine device or surgical sterilization. If necessary a negative urine or blood test will be performed before randomization
  17. Any condition that in the opinion of the investigator would jeopardize the evaluation for efficacy or safety or be associated with poor adherence to the protocol, including cognitive decline.
  18. \<1 year;
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • No intervention
    Control

    Heart failure clinic follow up

  • Active comparator
    CardioMems

    The treatment group will be implanted with a CardioMEMS HF sensor and managed using remote access to hemodynamics compared to a non-implanted control group.

    Device: CardioMems

Interventions

  • DeviceCardioMems

    novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System

06

What researchers measure

Primary outcomes

  1. first occurrence of any component of the composite event

    acute decompensated heart failure requiring emergency department consultation

    Time frame: 12 months

  2. Number of Participants with unplanned intravenous heart failure therapy in an outpatient clinic

    unplanned intravenous heart failure therapy in an outpatient clinic

    Time frame: 12 months

  3. Number of Participants with hospital admission for heart failure

    hospital admission for heart failure

    Time frame: 12 months

  4. Number of Participants with cardiovascular (CV) death

    cardiovascular (CV) death

    Time frame: 12 months

Secondary outcomes

  1. Time to the first occurrence of the individual components of the primary endpoint

    Acute decompensated heart failure that requires emergency department consultation and/or unplanned intravenous heart failure therapy in an outpatient clinic

    Time frame: 12 months

  2. Number of Participants with CV death

    CV death

    Time frame: 12 months

  3. Change in Quality of life

    Quality of life questionnaire

    Time frame: 12 months

  4. Change in functional capacity between baseline and 12-months

    NYHA functional class (Kansas city cardiomyopathy questionnaire)

    Time frame: 12 months

  5. Change in 6 minutes walk distance

    6 minutes walk distance test

    Time frame: 12 months

  6. Number of Participants with device-related endpoints

    Safety: adverse events related to the device

    Time frame: 12 months

  7. Number of successful patient contacts

    Number of successful patient contacts

    Time frame: 12 months

  8. Pulmonary artery pressures changes mesured by the CardioMems device

    Pulmonary artery pressures changes mesured by the CardioMems device

    Time frame: 12 months

  9. Cost-effectiveness

    cost-effectiveness ratio

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Dec 2025, 67 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 67 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2020
First posted
Jun 22, 2020
StartActual
May 4, 2020
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04441203
Responsible party
Anique Ducharme (MD, MSc. Director of the Heart Failure clinic, Montreal Heart Institute) — Principal investigator
First posted
Jun 22, 2020
Start date
May 4, 2020
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 22, 2024

Study contacts

Anique Ducharme, MD
Contact
anique.ducharme@umontreal.ca
5143763330 ext. 3947
Hélène Brown, BSc CCRP
Contact
helene.brown@icm-mhi.org
5143763330 ext. 3931
Anique Ducharme
principal investigator · Montreal Heart Institute
Jean Rouleau, MD
study director · Montreal Heart Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion